This dosage information may not include all the information needed to use Pazopanib safely and effectively. See additional information for Pazopanib.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Renal Cell Carcinoma
Recommended dose: 800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal)
The dose of pazopanib should not exceed 800 mg.
Do not crush tablets due to the potential for increased rate of absorption which may affect systemic exposure.
If a dose is missed, it should not be taken if it is less than 12 hours until the next dose.
Renal Dose Adjustments
Because renal impairment is not expected to influence pazopanib exposure, dose adjustment is not necessary.
Liver Dose Adjustments
The dosage of pazopanib in patients with moderate hepatic impairment should be reduced to 200 mg per day.
There are no data in patients with severe hepatic impairment. Therefore, the use of pazopanib is not recommended in patients with severe hepatic impairment.
The initial dose reduction should be 400 mg. Additional dose decreases or increases should be in 200 mg steps based on individual tolerability. The dose of pazopanib should not exceed 800 mg.
Concomitant Strong CYP450 3A4 Inhibitors:
The concomitant use of strong CYP450 3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin) may increase pazopanib concentrations and should be avoided. If coadministration of a strong CYP450 3A4 inhibitor is warranted, reduce the dose of pazopanib to 400 mg. Further dose reductions may be needed if adverse effects occur during therapy. This dose is predicted to adjust the pazopanib AUC to the range observed without inhibitors. However, there are no clinical data with this dose adjustment in patients receiving strong CYP450 3A4 inhibitors.
Concomitant Strong CYP450 3A4 Inducer:
The concomitant use of strong CYP450 3A4 inducers (e.g., rifampin) may decrease pazopanib concentrations and should be avoided. Pazopanib should not be used in patients who cannot avoid chronic use of strong CYP450 3A4 inducers.
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Data not available